Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Current evidence on tapering of tumor necrosis factor inhibitors (TNFi) in axial
spondyloarthritis (axSpA) is still hampered by heterogeneity in tapering regimens, selection
and performance biases, and lack of data on optimized treatment dosing strategies especially
in real-world clinical settings. This study aims to contribute to the ongoing investigation
of disease-activity-guided tapering of TNFi in axSpA in the form of a prospective, randomized
controlled trial.